Eli Lil­ly's Alzheimer’s win; Astel­las joins buy­er­s' club with $5.9B deal; $540M biotech IPO; His­toric RSV vac­cine OK; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

What a week! We’ve packed quite a bit in this is­sue, in­clud­ing a lot of in-depth, orig­i­nal re­port­ing. If you had any of these sto­ries open in a tab but hadn’t got­ten to it yet, grab a cof­fee and dig in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.